Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ingested Interferon-Alpha in Newly Diagnosed Type 1 Diabetes
NCT00024518Phase 2Completed
- Sponsor
- UTHealth Houston
- Start
- Sep 2001
- Primary completion
- Sep 2008
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of interferon alfa in type 1 diabetes mellitus (T1D) (3 arms), sponsored by UTHealth Houston. Primary endpoint: C-Peptide Level at 12 months. Started Sep 2001; status: completed.
02
Drugs
interferon alfa
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT00024518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00024518.